HALO HALOZYME THERAPEUTICS INC
2026Q1 · CUSIP 40637H109 · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
627
Δ holders QoQ
+16
Breadth percentile
Top 19%
Whale holders
238
Δ whales
-2
Inst. holding value
$7.7B
New positions
97
Closed positions
81
Price momentum (1Q)
-16.2%
Put / Call
8/9
Breadth history (34 quarters)
Past Lit Events & Aftermath 11 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 19% | — | — |
| 2025Q3 | Top 4% | +2.1% | -2.2% |
| 2025Q1 | Top 4% | +31.3% | +32.4% |
| 2024Q3 | Top 4% | +35.7% | +26.3% |
| 2024Q2 | Top 3% | -9.2% | -2.8% |
| 2023Q3 | Top 9% | -8.9% | +13.8% |
| 2022Q4 | Top 4% | -32.4% | -12.2% |
| 2022Q2 | Top 1% | +21.2% | +10.6% |
Options Sentiment
Put holders
8
QoQ: +1
Call holders
9
QoQ: 0
See methodology →
Fundamentals
PE (TTM)
27.0
EPS (TTM)
$2.85
EPS YoY
-24.2%
Revenue (TTM)
$1.5B
Revenue YoY
+39.1%
Net margin
23.1%
ROE
158.8%
Debt ratio
91.8%
FCF (TTM)
$668M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.